BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,156,539 | -22.3% | 57,142 | -6.2% | 0.01% | -20.0% |
| Q2 2023 | $2,774,285 | -29.3% | 60,893 | -39.2% | 0.01% | -33.3% |
| Q1 2023 | $3,921,259 | -24.3% | 100,158 | -5.0% | 0.02% | -21.1% |
| Q4 2022 | $5,180,692 | -4.1% | 105,437 | +1.3% | 0.02% | -17.4% |
| Q3 2022 | $5,404,000 | -16.5% | 104,135 | -0.5% | 0.02% | -11.5% |
| Q2 2022 | $6,468,000 | -21.4% | 104,685 | -1.3% | 0.03% | -3.7% |
| Q1 2022 | $8,225,000 | -23.0% | 106,085 | -14.7% | 0.03% | -22.9% |
| Q4 2021 | $10,678,000 | -14.0% | 124,396 | -19.4% | 0.04% | -23.9% |
| Q3 2021 | $12,416,000 | -26.2% | 154,372 | -26.1% | 0.05% | -24.6% |
| Q2 2021 | $16,815,000 | -40.6% | 208,885 | -37.7% | 0.06% | -50.0% |
| Q1 2021 | $28,287,000 | +9.5% | 335,402 | +4.2% | 0.12% | -1.6% |
| Q4 2020 | $25,835,000 | +29.7% | 321,981 | +30.0% | 0.12% | +20.4% |
| Q3 2020 | $19,922,000 | +109.9% | 247,732 | +124.8% | 0.10% | +87.3% |
| Q2 2020 | $9,489,000 | +5.1% | 110,212 | -0.9% | 0.06% | -6.8% |
| Q1 2020 | $9,029,000 | -4.3% | 111,212 | -1.4% | 0.06% | +25.5% |
| Q4 2019 | $9,435,000 | +88.3% | 112,835 | +97.0% | 0.05% | +67.9% |
| Q3 2019 | $5,010,000 | +7.2% | 57,281 | +0.3% | 0.03% | +7.7% |
| Q2 2019 | $4,675,000 | +2.3% | 57,090 | +1.6% | 0.03% | 0.0% |
| Q1 2019 | $4,568,000 | +25.5% | 56,186 | +1.6% | 0.03% | +13.0% |
| Q4 2018 | $3,639,000 | -16.6% | 55,293 | -2.3% | 0.02% | 0.0% |
| Q3 2018 | $4,362,000 | +4.6% | 56,593 | +0.2% | 0.02% | -4.2% |
| Q2 2018 | $4,171,000 | +13.5% | 56,493 | 0.0% | 0.02% | +14.3% |
| Q1 2018 | $3,674,000 | +0.6% | 56,493 | 0.0% | 0.02% | +5.0% |
| Q4 2017 | $3,651,000 | +0.5% | 56,493 | -2.4% | 0.02% | -4.8% |
| Q3 2017 | $3,633,000 | +2.8% | 57,897 | -0.8% | 0.02% | 0.0% |
| Q2 2017 | $3,535,000 | +11.8% | 58,393 | -4.2% | 0.02% | +10.5% |
| Q1 2017 | $3,162,000 | +17.0% | 60,973 | 0.0% | 0.02% | +18.8% |
| Q4 2016 | $2,703,000 | -11.6% | 60,973 | -5.1% | 0.02% | -15.8% |
| Q3 2016 | $3,059,000 | +0.8% | 64,274 | -4.2% | 0.02% | 0.0% |
| Q2 2016 | $3,034,000 | -2.2% | 67,107 | -11.1% | 0.02% | 0.0% |
| Q1 2016 | $3,101,000 | +8.4% | 75,499 | +0.7% | 0.02% | +5.6% |
| Q4 2015 | $2,860,000 | +15.7% | 74,979 | -0.4% | 0.02% | +12.5% |
| Q3 2015 | $2,471,000 | -54.1% | 75,246 | -2.2% | 0.02% | -50.0% |
| Q2 2015 | $5,378,000 | +0.6% | 76,915 | -1.5% | 0.03% | +3.2% |
| Q1 2015 | $5,347,000 | -93.6% | 78,065 | -93.2% | 0.03% | -93.5% |
| Q4 2014 | $84,175,000 | -1.1% | 1,148,524 | -3.2% | 0.48% | -3.6% |
| Q3 2014 | $85,144,000 | -8.8% | 1,186,353 | -8.2% | 0.50% | -16.4% |
| Q2 2014 | $93,408,000 | +0.7% | 1,291,962 | +2.5% | 0.59% | -3.1% |
| Q1 2014 | $92,771,000 | +5.1% | 1,260,820 | -0.7% | 0.61% | +4.8% |
| Q4 2013 | $88,266,000 | +5.3% | 1,269,105 | -0.5% | 0.58% | -0.3% |
| Q3 2013 | $83,814,000 | -9.9% | 1,275,913 | -0.1% | 0.58% | -8.6% |
| Q2 2013 | $92,990,000 | – | 1,276,813 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |